February 2026 Research Update

This month added several early signals that specific pathways in hereditary spastic paraplegia (HSP) might be targetable, but the evidence is mainly from patient cells, organoids, flies, or mice rather than from clinical trials. Across these studies, the common pattern was that adjusting a disrupted cell process (microtubules, mitochondrial function, or calpain signaling) moved disease-like cell and movement measures in a healthier direction. This helps clarify what may be driving symptoms in some genetic forms of HSP, while still leaving open whether these approaches will help people in day-to-day life. [1] [2] [3]

For SPG4 (SPAST-related HSP), an organoid model enriched for corticospinal motor neurons showed that SPAST mutations were linked to lower microtubule acetylation and axon damage, and the researchers identified increased HDAC6 activity as a key driver. In this lab setting, the HDAC6 inhibitor tubastatin A restored microtubule acetylation and reduced axon degeneration in organoids, and it was also linked to improved gait and better corticospinal tract measures in SPG4 transgenic mice. In plain terms, this work connects a specific biochemical change to nerve cell injury in SPG4 and shows that blocking that change can reverse several disease-like features in models. [1]

For SPG76 (CAPN1-related HSP), patient fibroblasts showed disturbed pro-survival signaling and more cell death, and the study tested drugs aimed at calming overactive calpain signaling and boosting survival pathways. Several compounds improved cell survival signals, and olesoxime and MDL28170 also improved movement problems in a matching fruit fly model. This adds weight to the idea that calpain pathway imbalance may be one workable target in SPG76, at least in experimental systems. [2]

In infantile-onset ascending hereditary spastic paralysis (ALS2/alsin-related), one study combined computer modeling with testing in a single patient-derived fibroblast line and reported that MK4 (menatetrenone) increased ALSIN levels and improved a measured feature of mitochondrial shape. The same cells also showed higher oxidative stress, which fits with the study's focus on mitochondrial stress as part of the disease picture. This is a very early step that mainly shows a possible direction for research rather than an established therapy. [3]

These studies may matter more later than now, because they are not tests of benefit in patients and do not show how symptoms change in everyday life. What became clearer this month is that multiple HSP forms can be studied in human-derived nerve cell models, and that certain targeted approaches can reverse specific disease-like changes in those systems. What remains uncertain is whether the same targets (HDAC6 in SPG4, calpain signaling in SPG76, or mitochondrial stress in ALS2-related disease) will translate into safe and meaningful improvements for people, and which genetic subtypes would benefit most. [1] [2] [3]

This month strengthened a broader picture that HSP symptoms can be shaped by more than one genetic change, and that different HSP genes can disrupt nerve cells through different cell pathways. Several studies tied specific DNA changes to measurable effects such as altered splicing, reduced key proteins, or mitochondrial energy problems. Together, they help explain why people with "the same" HSP label can have different symptoms, and why genetics sometimes requires deeper testing to find the full cause. [4] [5] [6] [7]

Two studies focused on SPG4 (SPAST). One reported that two intronic SPAST variants disrupted splicing in two families and were described as co-segregating with anorexia nervosa symptoms, which broadens the reported symptom range seen alongside SPG4 in these families. Another study described a proband who carried both a SPAST variant and a GJA1 R148Q variant, and lab work suggested GJA1 R148Q could lower SPASTIN levels by destabilizing a deubiquitinase (VCPIP1), while relatives with GJA1 R148Q alone had no neurologic abnormalities. In plain terms, these reports support that non-coding changes can matter in SPG4, and that a second variant in another gene might sometimes intensify SPG4 biology in a way that would not cause disease on its own. [5] [4]

A separate cell-based study connected HPDL loss-of-function to weaker mitochondrial respiratory chain assembly and higher oxidative stress, and patient-derived neurons and organoids showed early shifts toward neuron formation and poor growth. Treatments aimed at reducing oxidative stress or supporting coenzyme Q biology partially improved premature neurogenesis in some patient lines, but not all, suggesting mutation-specific differences. This adds to the idea that, in some complex spastic paraplegia conditions, energy production and oxidative stress can be central parts of the disease process even before discussing walking symptoms. [6]

One family study reported an ATL1 variant (p.Pro342Ser) that tracked with SPG3A across 3 generations, expanding the list of variants linked to this form of HSP. This kind of evidence matters because it helps families and researchers connect a specific DNA change to a consistent pattern of symptoms within a family. It also supports more accurate genetic answers when similar variants are found in other people. [7]

These studies mainly add understanding rather than changing care, but they can affect how people think about genetic results and symptom differences within families. What became clearer is that HSP can involve splicing problems in SPAST, possible gene-gene interactions that change how strongly SPG4 biology shows up, and mitochondrial energy problems in HPDL-related disease that may respond differently depending on the exact mutation. What remains uncertain is how often these patterns apply beyond the reported families and cell lines, and which findings will translate into tests or treatments used in routine care. [4] [5] [6] [7]

This month included human-focused studies that tackled two practical questions: can a blood test track HSP changes over time, and how can genetic testing miss important answers. The overall pattern was that a proposed blood marker looked stable over short follow-up in children, while deeper DNA and RNA testing found important hidden variants in a separate HSP gene case. Together, this clarifies that tracking disease activity and getting a complete genetic diagnosis can be challenging, and progress may come in steps rather than with a single simple test. [8] [9]

In 40 children with HSP, plasma neurofilament light chain (a blood marker of nerve cell injury) did not clearly separate genetic subtypes, levels of mobility limitation, or pure versus complex presentations at baseline. In the 31 children followed over time, levels stayed similar over a median of 9 months. The study also noted higher levels tended to appear in children with shorter time since symptom onset, suggesting this marker may be more informative closer to the beginning of disease, although this was not presented as a definitive rule. [8]

One case report in SPG7 showed how genome sequencing can uncover a second disease-causing change when earlier gene panel testing finds only one coding variant. In this person, a deep intronic variant was shown by RNA testing to cause abnormal splicing, and family testing supported that the two variants were on different copies of the gene. In plain terms, the report illustrates that some genetic causes can hide outside the usual regions tested, and RNA evidence can help confirm whether a non-coding change is truly disruptive. [9]

For families hoping for simple monitoring tests, this month suggests that one blood marker (plasma neurofilament light chain) may not change much over about 9 months in pediatric HSP, and it may not neatly match day-to-day function or genetic subtype. For families still seeking a genetic answer, the SPG7 case shows that non-coding variants can be missed by some tests and may require genome and RNA-based approaches to be found and confirmed. What remains uncertain is whether longer follow-up, different markers, or different patient groups will make blood-based tracking more useful, and how often hidden SPG7 variants explain unresolved cases. [8] [9]

This month’s case reports mostly expanded the range of genetic findings and clinical presentations seen alongside spastic paraplegia, rather than establishing new generalizable treatments. Across different ages, single-patient reports described newly identified variants (AP4M1 and KIF5A) and one example of combined spasticity treatment and robot-assisted gait training with short-term functional changes. The main value is showing what can occur in individual situations, while recognizing that a single case cannot predict what will happen for others. [10] [11] [12]

On the genetics side, one child with SPG50 had a new AP4M1 frameshift variant, with modeling suggesting loss of function, and the clinical picture included seizures, intellectual disability, weakness, and MRI white matter changes. Another adult case described a new likely pathogenic KIF5A variant in a person with spastic paraplegia alongside parkinsonism that responded to levodopa, ataxia, and neuropathy. These reports add to the catalog of variants and remind readers that some gene-related syndromes can mix spasticity with other neurologic symptoms. [10] [11]

On rehabilitation and symptom management, one report described intrathecal baclofen followed by Hybrid Assistive Limb (HAL) assisted gait training in a man in his 60s with HSP. Over 70 days, walking speed did not change, but walking endurance (2-minute walk distance) and sit-to-stand performance improved, and posture measures during gait shifted in a way that could reflect smoother stepping mechanics. No adverse events were reported in this single case, but the report cannot show whether the same pattern would hold in other people or over longer periods. [12]

These reports may matter now mainly as awareness, since they show the range of genetic findings and mixed symptom combinations that can occur in HSP-related conditions. They may matter later if additional patients with the same variants are reported, which can help confirm whether a variant consistently causes a specific pattern of symptoms. The rehabilitation case provides a concrete example of short-term changes seen with intrathecal baclofen plus HAL training, but it remains uncertain how durable or widely applicable those changes are because it was only 1 person. [10] [11] [12]